Today, we will see why it will be better for investors to remain on the fence for Alkermes (ALKS) in March 2020.
Company overview
Alkermes is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies targeting CNS (central nervous system) disorders such as schizophrenia, depression, addiction, and multiple sclerosis. The company's leading assets include VIVITROL in opioid abuse indication and the Aristada franchise in schizophrenia indication. Headquartered in Dublin, Ireland, the company was founded in 1987 and went public in 1991.